Thomas Schénke

Title: Thomas Schenke: Innovator in Pharmaceutical Treatments

Introduction

Thomas Schenke is a notable inventor based in Gladbach, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of infections and associated gastroduodenal diseases. His innovative work has led to the development of valuable therapeutic agents.

Latest Patents

Thomas Schenke holds a patent for the invention titled "Use of 7-(2-OXA-5,8-DIAZABICYLCO[4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELIOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES." This patent focuses on the use of quinolone- and naphthyridonecarboxylic acid derivatives, which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl radical. These compounds are designed for the therapy of infections and the gastroduodenal disorders associated with them. He has 1 patent to his name.

Career Highlights

Thomas Schenke is associated with Bayer Aktiengesellschaft, a leading global pharmaceutical company. His work at Bayer has allowed him to contribute to the development of innovative treatments that address critical health issues. His expertise in pharmaceutical chemistry has been instrumental in advancing therapeutic options for patients.

Collaborations

Throughout his career, Thomas has collaborated with notable colleagues, including Michael Matzke and Uwe Petersen. These collaborations have fostered a productive environment for innovation and research within the pharmaceutical sector.

Conclusion

Thomas Schenke's contributions to the field of pharmaceuticals exemplify the impact of innovative thinking in addressing health challenges. His patent work and collaborations highlight the importance of teamwork in advancing medical science.